Shots: DarwinHealth will receive an upfront and eligible to receive as a commercial milestone, as part of the NCTI collaboration The focus of the collaboration is to identify NCTs across […]readmore
Tags : Novel
Shots: The acquisition expands SparingVision’s ocular genomic medicine pipeline with the addition of GAMUT’s lead product SPVN20, which is a novel, mutation-agnostic gene therapy, focuses on restoring the function of […]readmore
Shots: Genevant to receive up to $600M up front and milestone as well as royalties on future product sales Takeda get exclusive rights to access Genevant’s LNP technology for a […]readmore
Shots: Janux to receive up to $500.5M/ target as upfront and milestones along with royalties on sales of product emerges from the collaboration, making a total deal value ~$1B. Merck […]readmore
Shots: KaliVir to receive $56M as upfront & other payments supporting the research & preclinical activities of VET2-L2 & is eligible to receive $307M & $271M as development, regulatory & […]readmore
Shots: Artios to receive $30M up front & near-term milestones, ~$860M/ target as option fee along with royalties on sales of each commercialized product. Additionally, Artios has opt-in rights for […]readmore
Shots: Janssen acquires rights to Hemera’s HMR59, administered as a one-time, outpatient, IVT inj. to help preserve vision in patients with geographic atrophy The acquisition will boost Janssen’s eye disease […]readmore
Shots: NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate PostEra will use its ML […]readmore
Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential […]readmore
Shots: Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development, regulatory and commercial expertise Pfizer will […]readmore